A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Sucroferric oxyhydroxide (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions; Registrational
- Sponsors Kissei Pharmaceutical
- 12 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2014 New trial record